查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1557323

肺炎链球菌疫苗市场 - 2024 年至 2029 年预测

Pneumococcal Vaccines Market - Forecasts from 2024 to 2029
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 110 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

全球肺炎链球菌疫苗市场预计将以 6.49% 的复合年增长率成长，从 2024 年的 94.45 亿美元增至 2029 年的 129.32 亿美元。

有助于预防由肺炎链球菌引起的肺炎球菌疾病的疫苗被归类为肺炎球菌疫苗。虽然肺炎球菌疾病在幼儿中最常见，但成人和老年人更容易受到肺炎球菌污染，甚至可能致命。疫苗接种是预防疾病传播的广泛接受的形式之一，并且正在推动对肺炎疫苗的需求。

定期国家疫苗接种计划的实施正在支持市场成长。其次，人们对肺炎的认识不断提高，世界卫生组织和联合国儿童基金会发布的指令以及政府支持的增加正在支持当前情况下的市场扩张。

肺炎链球菌疫苗的全球市场驱动因素

  • 儿童肺炎发病率的增加预计将推动对肺炎球菌疫苗的需求。

在儿童流行的感染疾病中，肺炎占儿童死亡率的比例最高。每年有超过 80 万名五岁以下儿童死于肺炎，即每天约有 2,200 名儿童。其中约 153,000 人是新生儿。根据联合国儿童基金会的资料，每年每10万人就有1,400人罹患肺炎，即71人中就有1人罹患肺炎。

南亚的发生率最高，为每 10 万名儿童 2,500 例，西非和中非的发生率最高，为每 10 万名儿童 1,620 例。这些数字对降低儿童死亡率、增加对肺炎球菌疫苗的需求和鼓励市场扩张造成了令人震惊的局面。

  • 疾病意识提升宣传活动和政府政策正在提供新的成长前景。

肺炎链球菌疫苗主要接种给 2 岁以上的儿童，以保护他们免受肺炎球菌引起的疾病。因此，世界卫生组织、联合国儿童基金会和联合国开发计画署等多个国际组织正在与各国政府合作，降低肺炎感染的发生率，特别是特别容易感染此类疾病的儿童和老年人。

疫苗计划的实施，例如卫生署根据全民免疫计划在全国范围内推广肺炎球菌结合疫苗（PCV），有助于传播对肺炎的认识，并为五岁以下儿童提供适当的疫苗。免疫系统。这些计划和政策正在透过推出新产品和扩大现有产品系列来提振疫苗市场。

同样，肺炎高发生率的各个低度开发国家也得到了国际组织的援助。例如，根据联合国儿童基金会 2024 年 3 月的新闻稿，伊朗收到了约 564,000 剂肺炎球菌结合疫苗 (PCV)，以防止肺炎球菌相关感染疾病在儿童中传播。在这样的支持下，肺炎链球菌疫苗的市场正在不断成长。

全球肺炎链球菌疫苗区隔市场分析

  • 预计结合疫苗将在特定时期内显着成长。

依种类，国际上的肺炎链球菌疫苗可分为结合疫苗和多醣体疫苗。前者预计将出现显着增长，因为它提供了针对肺炎和脑膜炎等疾病的免疫力，这些疾病主要发生在婴幼儿和 65 岁以上的成年人中。对抗此类疾病的疫苗开发进展是该领域成长的主要动力。

例如，2023年4月，辉瑞宣布其PREVNAR 20(R)疫苗已获得食品药物管理局的核准。该疫苗可保护 6 週至 17 岁的婴幼儿和儿童免受肺炎球菌引起的侵袭性肺炎链球菌感染。

预计北美将占据重要的市场占有率。

从地区来看，全球市场分为北美、南美、欧洲、中东/非洲、亚太地区五个主要区域。由于持续努力遏制儿童肺炎的传播，预计北美将占据重要的市场占有率。因此，美国FDA 等主要监管机构已核准某些疫苗。

例如，2024年6月，默克公司宣布旨在为50岁及以上的成年人提供主动疫苗接种，覆盖至少84%的由肺炎球菌血清型引起的侵袭性外科疾病。 FDA核准。同样，各种生技疫苗製造商也处于肺炎链球菌疫苗开发倡议阶段。例如，2024年1月，Vaxcyte Inc.宣布完成其VAX-31肺炎链球菌结合疫苗的临床1/2期註册，用于预防50岁及以上成年人的IPD（侵袭性肺炎链球菌感染）。

除了肺炎球菌疫苗的开发取得进展外，儿童肺炎盛行率的不断上升也推动了整个北美市场的成长。例如，根据疾病预防控制中心提供的小儿肺炎最新信息，截至2023年11月，0至1岁儿童肺炎急诊就诊率为1.7%，2岁儿童为2.4%至4岁儿童，2至4岁儿童为2.4%。

限制全球肺炎链球菌疫苗市场的因素：

  • 疫苗生产成本高昂预计将阻碍整体市场成长。

疫苗生产过程的高成本和长週期是市场成长的挑战。此外，疫苗必须经历的各个阶段都需要适当的测试和监测才能达到预期的结果，这非常耗时。然而，政府对疫苗生产的补贴和国际组织宣布的资金正在帮助克服这一障碍。

全球肺炎链球菌疫苗主要市场开拓：

  • 2024年1月，辉瑞宣布CHMP（人用药品委员会）对核准该公司的「20vPnC」采取了积极意见。
  • 2023 年 10 月，Vaxcyte Inc. 与 Lonza 签订了商业生产协议，以加强 Vaxcyte 的 PCV 候选药物「VAX-31」和「VAX-24」的生产和商业化，以改善成人和老年人群的疾病控制。的传播.此次合作利用了 Lonza 的自订製造套件和基础设施。

全球肺炎链球菌疫苗市场細項分析如下：

按类型

  • 结合疫苗
  • 多醣体疫苗

按用途

  • 常规疫苗接种
  • 疾病/感染疾病接种

按地区

  • 北美洲
  • 美国
  • 加拿大
  • 墨西哥
  • 南美洲
  • 巴西
  • 阿根廷
  • 其他的
  • 欧洲
  • 美国英国
  • 德国
  • 法国
  • 义大利
  • 西班牙
  • 其他的
  • 中东/非洲
  • 沙乌地阿拉伯
  • 以色列
  • 其他的
  • 亚太地区
  • 日本
  • 中国
  • 印度
  • 印尼
  • 台湾
  • 泰国
  • 其他的

目录

第一章简介

  • 市场概况
  • 市场定义
  • 调查范围
  • 市场区隔
  • 货币
  • 先决条件
  • 基准年和预测年时间表
  • 相关利益者的主要利益

第二章调查方法

  • 研究设计
  • 调查过程

第三章执行摘要

  • 主要发现

第四章市场动态

  • 市场驱动因素
  • 市场限制因素
  • 波特五力分析
  • 产业价值链分析
  • 分析师观点

第五章全球肺炎链球菌疫苗市场：按类型

  • 介绍
  • 结合疫苗
  • 多醣体疫苗

第六章全球肺炎链球菌疫苗市场：依应用分类

  • 介绍
  • 常规疫苗接种
  • 疾病/感染疾病接种

第七章 按地区分類的肺炎链球菌市场

  • 介绍
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他的
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 其他的
  • 中东/非洲
    • 沙乌地阿拉伯
    • 以色列
    • 其他的
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 印尼
    • 台湾
    • 泰国
    • 其他的

第八章竞争环境及分析

  • 主要企业及策略分析
  • 市场占有率分析
  • 合併、收购、协议和合作
  • 竞争对手仪表板

第九章 公司简介

  • Pfizer
  • GSK
  • Merck
  • AstraZeneca
  • Serum Institute of India Pvt Ltd
简介目录
Product Code: KSI061612059

The global pneumococcal vaccine market is estimated to grow at a CAGR of 6.49% and reach US$12.932 billion in 2029 from US$9.445 billion in 2024.

Vaccines that help prevent pneumococcal disease caused by Streptococcus pneumoniae bacteria are classified as pneumococcal vaccines. Pneumococcal diseases are most common in younger children; however, adults and the elderly are more prone to pneumococcal contaminations and even death. Immunization is one of the widely accepted forms to prevent disease spread, driving the demand for pneumonia vaccines.

Major driving factors, such as the implementation of regular vaccination programs under the national policy, are aiding the market's growth. Secondly, rising awareness against pneumonia, directives launched by WHO and UNICEF, and increasing government support assist the market's expansion in the current scenario.

Global Pneumococcal Vaccine Market Drivers

  • The growing incidence of childhood pneumonia is expected to drive the demand for pneumococcal vaccines.

Among all the infectious diseases prevalent among children, pneumonia has the highest share of fatalities in children. More than 800 thousand children under the age of five lose their lives every year due to pneumonia, while the number is around 2.2 thousand per day. Around 153 thousand of those children are newborns. According to data from UNICEF, 1,400 cases per 100,000 children suffer from pneumonia every year, which makes it 1 out of 71 children.

The South Asian region has the highest incidence rate, with 2,500 cases per 100,000 children, while the West and Central African region has an incidence rate of 1,620 cases per 100,000 children. These numbers are creating an alarming situation to combat child mortality rates, which is expanding the demand for pneumococcal vaccines, thereby stimulating their market expansion.

  • Growing disease awareness campaigns and government policies have provided new growth prospects.

Pneumococcal vaccines are given primarily to children aged 2 years and above to protect them from illness caused by S. pneumoniae bacteria. Hence, various International organizations like WHO, UNICEF, and UNDP, in conjunction with the national government, are working to reduce pneumonia infection rates, especially among the children and older generation who are more susceptible to such diseases.

The implementation of vaccine programs such as the nationwide expansion of pneumococcal conjugate vaccine (PCV) launched by the Ministry of Health under the "Universal Immunization Program" aimed to spread awareness against pneumonia and boost the immune system of children aged under 5 years through appropriate vaccines. These plans and policies boost the vaccine market by introducing novel products and expanding the existing product portfolios.

Likewise, various underdeveloped countries with higher prevalence rates of pneumonia are receiving aid from international organizations. For instance, as per the March 2024 UNICEF press release, Iran received nearly 564,000 doses of pneumococcal conjugate vaccine (PCV) to prevent pneumococcal-related infection from spreading among children; the shipment arrived in Tehran on March 17. Such assistance has led to an upward market trajectory for pneumococcal vaccines.

Global Pneumococcal Vaccine Market Segment Analysis

  • The conjugate vaccine is expected to show significant growth during the given time frame.

By type, the global pneumococcal vaccine is analyzed into the conjugate vaccine and polysaccharide vaccine. The former is anticipated to show remarkable growth as it provides immunity against diseases such as pneumonia and meningitis, which are mostly found in infants and adults aged 65 years and above. The ongoing vaccination development to battle such illnesses has provided a major boost to the segment's growth.

For instance, in April 2023, Pfizer announced that the company received the Food and Drug Administration's approval for its "PREVNAR 20(R)" vaccine. This vaccine would protect infants and children aged six weeks to 17 years against invasive pneumococcal disease caused by 20 S. pneumoniae.

North America is anticipated to account for a considerable market share.

Based on geography, the global market is analyzed into five major regions, namely North America, South America, Europe, Middle East and Africa, and Asia Pacific. North America is estimated to constitute a remarkable market share, fuelled by the ongoing efforts to reduce pneumonia spread among children. This has led major governing authorities, such as the U.S. FDA, to grant approval to certain vaccines.

For instance, in June 2024, Merck received the U.S FDA's approval for its "CAPVAXIVE(TM)" vaccine, which is designed to provide active immunization to adults aged 50 years and above by covering at least 84% of invasive surgical diseases caused by S. pneumoniae serotypes. Likewise, various biotech vaccine manufacturers are in initiative phases for pneumococcal vaccine development. For instance, in January 2024, Vaxcyte Inc. announced the completion of enrolment for its clinical phase 1/2 to study the VAX-31 pneumococcal conjugate vaccine designed to prevent IPD (Invasive Pneumococcal Disease) in adults aged 50 years and above.

Besides the ongoing development of the pneumococcal vaccine, the growing prevalence of pneumonia in children is also driving the overall market growth in North America. For instance, according to the pediatric pneumonic update provided by the Center for Disease Control and Prevention, as of November 2023, the emergency visits diagnosed pneumonia stood at 1.7% for children aged 0 to 1 year, 2.4% for 2 to 4 years and 1.5% for 5 to 17 years.

Global Pneumococcal Vaccine Market Restraints:

  • The high cost of vaccine production is expected to hamper the overall market growth.

The high cost and long duration of the vaccine production process are challenging factors for market growth. Moreover, the various phases a vaccine has to go through require proper testing and monitoring to acquire the desired results, which is time-consuming. However, government subsidies on vaccine production and funds released by international organizations are helping to clear the hurdles in the path.

Global Pneumococcal Vaccine Key Market Development:

  • In January 2024, Pfizer announced that the CHMP (Committee for Medicinal Products for Humans) adopted a positive opinion regarding granting authorization to the company's "20vPnC." This will be used to prevent the spread of invasive diseases such as acute otitis and pneumonia in adults and children aged 6 weeks to 18 years.
  • In October 2023, Vaxcyte Inc. formed a commercial manufacturing agreement with Lonza to bolster the manufacturing and commercialization of Vaxcyte's PCV candidates "VAX-31" and "VAX-24" to prevent the disease spread in the adult and geriatric population. The collaboration will leverage Lonza's custom-manufacturing suite and infrastructure.

The Global Pneumococcal Vaccine market is segmented and analyzed as follows:

By Type

  • Conjugate Vaccines
  • Polysaccharide Vaccines

By Application

  • Routine Vaccination
  • Vaccination For Disease/Infection

By Geography

  • North America
  • United States
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • Israel
  • Others
  • Asia Pacific
  • Japan
  • China
  • India
  • Indonesia
  • Taiwan
  • Thailand
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base and Forecast Years Timeline
  • 1.8. Key Benefits for the Stakeholder

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Processes

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis
  • 4.5. Analyst View

5. GLOBAL PNEUMOCOCCAL VACCINES MARKET BY TYPE

  • 5.1. Introduction
  • 5.2. Conjugate Vaccines
  • 5.3. Polysaccharide Vaccines

6. GLOBAL PNEUMOCOCCAL VACCINES MARKET BY APPLICATION

  • 6.1. Introduction
  • 6.2. Routine Vaccination
  • 6.3. Vaccination for Disease/Infection

7. GLOBAL PNEUMOCOCCAL MARKET BY GEOGRAPHY

  • 7.1. Introduction
  • 7.2. North America
    • 7.2.1. United States
    • 7.2.2. Canada
    • 7.2.3. Mexico
  • 7.3. South America
    • 7.3.1. Brazil
    • 7.3.2. Argentina
    • 7.3.3. Others
  • 7.4. Europe
    • 7.4.1. United Kingdom
    • 7.4.2. Germany
    • 7.4.3. France
    • 7.4.4. Italy
    • 7.4.5. Spain
    • 7.4.6. Others
  • 7.5. Middle East and Africa
    • 7.5.1. Saudi Arabia
    • 7.5.2. Israel
    • 7.5.3. Others
  • 7.6. Asia Pacific
    • 7.6.1. Japan
    • 7.6.2. China
    • 7.6.3. India
    • 7.6.4. Indonesia
    • 7.6.5. Taiwan
    • 7.6.6. Thailand
    • 7.6.7. Others

8. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 8.1. Major Players and Strategy Analysis
  • 8.2. Market Share Analysis
  • 8.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 8.4. Competitive Dashboard

9. COMPANY PROFILES

  • 9.1. Pfizer
  • 9.2. GSK
  • 9.3. Merck
  • 9.4. AstraZeneca
  • 9.5. Serum Institute of India Pvt Ltd